Cargando…
Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients
INTRODUCTION: Immunocompromised patients infected with influenza exhibit prolonged viral shedding and higher risk of resistance. Optimized treatment strategies are needed to reduce the risk of antiviral resistance. This phase IIIb, randomized, double-blind study (NCT00545532) evaluated conventional-...
Autores principales: | Mitha, Essack, Krivan, Gergely, Jacobs, Frederique, Nagler, Arnon, Alrabaa, Sally, Mykietiuk, Analia, Kenwright, Andrew, Le Pogam, Sophie, Clinch, Barry, Vareikiene, Loreta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856247/ https://www.ncbi.nlm.nih.gov/pubmed/31667696 http://dx.doi.org/10.1007/s40121-019-00271-8 |
Ejemplares similares
-
Oseltamivir in pregnancy and birth outcomes
por: Ehrenstein, Vera, et al.
Publicado: (2018) -
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization
por: Sturm, Stefan, et al.
Publicado: (2020) -
Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants
por: Gibiansky, Leonid, et al.
Publicado: (2020) -
Progressive emergence of an oseltamivir‐resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient
por: Hurt, Aeron C., et al.
Publicado: (2013) -
1354. Nocardia bejingensis: A Novel Isolate Affecting Immunocompromised Patients in the United States
por: Moore-Pardo, Shylah M, et al.
Publicado: (2019)